{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:32:29Z","timestamp":1778689949441,"version":"3.51.4"},"reference-count":26,"publisher":"Pharmaceutical Society of Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,3,1]]},"DOI":"10.1248\/bpb.b25-00753","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T22:11:23Z","timestamp":1772316683000},"page":"422-428","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Feasibility of Nomogram-Based Vancomycin Dosing Strategy: A Retrospective Study"],"prefix":"10.1248","volume":"49","author":[{"given":"Naoto","family":"Okada","sequence":"first","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Yoshii","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Tamura","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anri","family":"Baba","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Matsudomi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Sakiyama","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Goto","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"},{"name":"Clinical Pharmacology, Yamaguchi University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus<\/i> infections in adults and children: executive summary. <i>Clin. Infect. Dis.<\/i>, <b>52<\/b>, 285\u2013292 (2011).","DOI":"10.1093\/cid\/cir034"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. <i>Am. J. Health Syst. Pharm.<\/i>, <b>66<\/b>, 82\u201398 (2009).","DOI":"10.2146\/ajhp080434"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Abdelmessih E, Patel N, Vekaria J, Crovetto B, SanFilippo S, Adams C, Brunetti L. Vancomycin area under the curve <i>versus<\/i> trough only guided dosing and the risk of acute kidney injury: systematic review and meta-analysis. <i>Pharmacotherapy<\/i>, <b>42<\/b>, 741\u2013753 (2022).","DOI":"10.1002\/phar.2722"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, Pai MP, Wong-Beringer A, Rotschafer JC, Rodvold KA, Maples HD, Lomaestro B. Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus<\/i> infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clin. Infect. Dis.<\/i>, <b>71<\/b>, 1361\u20131364 (2020).","DOI":"10.1093\/cid\/ciaa303"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Oda K, Hashiguchi Y, Kimura T, Tsuji Y, Shoji K, Takahashi Y, Matsumoto K, Kawamura H, Saito H, Takesue Y. Performance of area under the concentration-time curve estimations of vancomycin with limited sampling by a newly developed web application. <i>Pharm. Res.<\/i>, <b>38<\/b>, 637\u2013646 (2021).","DOI":"10.1007\/s11095-021-03030-y"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Maeda Y, Omoda K, Fukuhara S, Ohta M, Ishii Y, Murakami T. Evaluation of clinical efficacy of Maeda\u2019s nomogram for vancomycin dosage adjustment in adult Japanese MRSA pneumonia patients. <i>Drug Metab. Pharmacokinet.<\/i>, <b>21<\/b>, 54\u201360 (2006).","DOI":"10.2133\/dmpk.21.54"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. <i>J. Antimicrob. Chemother.<\/i>, <b>63<\/b>, 1050\u20131057 (2009).","DOI":"10.1093\/jac\/dkp085"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Ishii H, Hirai K, Sugiyama K, Nakatani E, Kimura M, Itoh K. Validation of a nomogram for achieving target trough concentration of vancomycin: accuracy in patients with augmented renal function. <i>Ther. Drug Monit.<\/i>, <b>40<\/b>, 693\u2013698 (2018).","DOI":"10.1097\/FTD.0000000000000562"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Matsuzaki T, Kato Y, Mizoguchi H, Yamada K. A machine learning model that emulates experts\u2019 decision making in vancomycin initial dose planning. <i>J. Pharmacol. Sci.<\/i>, <b>148<\/b>, 358\u2013363 (2022).","DOI":"10.1016\/j.jphs.2022.02.005"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Miyai T, Imai S, Yoshimura E, Kashiwagi H, Sato Y, Ueno H, Takekuma Y, Sugawara M. Machine learning-based model for estimating vancomycin maintenance dose to target the area under the concentration curve of 400-600\u2009mg.h\/L in Japanese patients. <i>Biol. Pharm. Bull.<\/i>, <b>45<\/b>, 1332\u20131339 (2022).","DOI":"10.1248\/bpb.b22-00305"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Okamoto G, Kawakami A, Ito D, Sawai M, Okano K, Kobayashi E. Use of nomograms based on the one-compartment model in the estimation of area under the blood concentration-time curve of vancomycin: a retrospective cohort study. <i>Eur. J. Clin. Pharmacol.<\/i>, <b>81<\/b>, 1583\u20131591 (2025).","DOI":"10.1007\/s00228-025-03885-9"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Oda K, Katanoda T, Hashiguchi Y, Kondo S, Narita Y, Iwamura K, Nosaka K, Jono H, Saito H. Development and evaluation of a vancomycin dosing nomogram to achieve the target area under the concentration-time curve. A retrospective study. <i>J. Infect. Chemother.<\/i>, <b>26<\/b>, 444\u2013450 (2020).","DOI":"10.1016\/j.jiac.2019.11.009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S, Hamada Y, Kimura T, Mayumi T, Ueda T, Nakajima K, Takesue Y. Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. <i>Pharmaceutics<\/i>, <b>14<\/b>, 489 (2022).","DOI":"10.3390\/pharmaceutics14030489"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Yamada K, Tsuchida T, Otani N, Takahashi Y, Ishihara M, Takubo S, Ikeuchi H, Uchino M, Kimura T, Matsumoto K, Oda K, Kimura T. Validation of vancomycin area under the concentration-time curve estimation by the bayesian approach using one-point samples for predicting clinical outcomes in patients with methicillin-resistant <i>Staphylococcus aureus<\/i> infections. <i>Antibiotics<\/i>, <b>11<\/b>, 96 (2022).","DOI":"10.3390\/antibiotics11010096"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. <i>Ther. Drug Monit.<\/i>, <b>16<\/b>, 513\u2013518 (1994).","DOI":"10.1097\/00007691-199410000-00013"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. <i>Am. J. Kidney Dis.<\/i>, <b>53<\/b>, 982\u2013992 (2009).","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Oda K, Hiyama Y, Ueda T, Furusho H, Yamada T, Katanoda T, Yoshikawa H, Tomita T, Ide T, Jingami S, Kusaka Y, Jono H, Saito H. Empirical dosage determination of vancomycin for a target area under the concentration-time curve of 400\u2009mug.h\/mL in the first 24\u2009h: a prospective multicenter observational study with rich sampling. <i>Br. J. Clin. Pharmacol.<\/i>, <b>91<\/b>, 1914\u20131926 (2025).","DOI":"10.1002\/bcp.70002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Oda K, Jono H, Nosaka K, Saito H. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15\u201320\u2009mug\/mL concentration. <i>Int. J. Antimicrob. Agents<\/i>, <b>56<\/b>, 106109 (2020).","DOI":"10.1016\/j.ijantimicag.2020.106109"},{"key":"19","unstructured":"19) Ostermann M, Bellomo R, Burdmann EA, <i>et al.<\/i> Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. <i>Kidney Int.<\/i>, <b>98<\/b>, 294\u2013309 (2020)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kondo M, Nakagawa S, Orii S, Itohara K, Sugimoto M, Omura T, Sato Y, Imai S, Yonezawa A, Nakagawa T, Matsubara K. Association of initial trough concentrations of vancomycin with outcomes in pediatric patients with gram-positive bacterial infection. <i>Biol. Pharm. Bull.<\/i>, <b>43<\/b>, 1463\u20131468 (2020).","DOI":"10.1248\/bpb.b19-01003"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Knight JM, Iso T, Perez KK, Swan JT, Janak CE, Ikwuagwu JO, Musick WL. Risk of acute kidney injury based on vancomycin target trough attainment strategy: area-under-the-curve-guided bayesian software, nomogram, or trough-guided dosing. <i>Ann. Pharmacother.<\/i>, <b>58<\/b>, 110\u2013117 (2024).","DOI":"10.1177\/10600280231171373"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Lines J, Burchette J, Kullab SM, Lewis P. Evaluation of a trough-only extrapolated area under the curve vancomycin dosing method on clinical outcomes. <i>Int. J. Clin. Pharm.<\/i>, <b>43<\/b>, 263\u2013269 (2021).","DOI":"10.1007\/s11096-020-01157-3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Iida M, Horita Y, Asaoka M, Ohashi K, Noda M, Wachino C, Hirose T, Nomura Y, Hisada Y, Nagamizu M, Kawahara M, Morishita N, Kondo M, Hotta Y, Nakamura A, Furukawa-Hibi Y. Evaluation of target area under the concentration-time curve of vancomycin in an initial dosing design: a retrospective cohort study. <i>J. Antimicrob. Chemother.<\/i>, <b>79<\/b>, 2518\u20132527 (2024).","DOI":"10.1093\/jac\/dkae249"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ishigo T, Suzuki A, Ibe Y, <i>et al.<\/i> Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study. <i>J. Pharm. Health Care Sci.<\/i>, <b>11<\/b>, 44 (2025).","DOI":"10.1186\/s40780-025-00452-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ortwine JK, Zasowski EJ, Pogue JM, Hanni C, Giuliano C, Casapao AM, Mynatt R, Rybak MJ. Relationship status between vancomycin loading dose and treatment failure in patients with MRSA bacteremia: it\u2019s complicated. <i>Infect. Dis. Ther.<\/i>, <b>8<\/b>, 627\u2013640 (2019).","DOI":"10.1007\/s40121-019-00268-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Chung D, Efta J, Brunsman A, Gabriel J, Johnson J, Martz C, Stuart M, Kenney R, Smith Z. Evaluation of pharmacist time dedicated to vancomycin dosing in adult patients using a 24-hour AUC nomogram or trough monitoring approach: a time motion study. <i>Am. J. Health Syst. Pharm.<\/i>, <b>79<\/b>, 1173\u20131179 (2022).","DOI":"10.1093\/ajhp\/zxac094"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/3\/49_b25-00753\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:01:52Z","timestamp":1772856112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/3\/49_b25-00753\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00753","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"article-number":"b25-00753"}}